IL28B SNP rs12979860 is the critical predictor for sustained viral response in Chinese children aged 1 to 6 years with chronic hepatitis C

International Journal of Biological Sciences

Volumn 12, Issue 11, 2016, Pages 1357-1362

  Zhong, Yan Wei ^a   Zhang, Hong Fei ^a   Shi, Yan Min ^b   Li, Yong Li ^a   Chu, Fang ^a   Xu, Zhi Qiang ^a   Chen, Da Wei ^a   Gan, Yu ^a   Wang, Fu Chuan ^a   Gu, Mei Lei ^a   Dong, Yi ^a   Zhu, Shi Shu ^a   Shi, Ce ^a   Fan, Hua Hao ^a   Zhang, Xiu Chang ^b   Zhang, Min ^a  

^a BEIJING 302 HOSPITAL   (China)

^b HEBEI NORTH UNIVERSITY   (China)

Author keywords

Chronic hepatitis C; IL 28B rs12979860

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

CHILD; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; GENETICS; GENOTYPE; HEPATITIS C, CHRONIC; HUMAN; INFANT; MALE; PATHOLOGY; PRESCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGIC RESPONSE; VIROLOGY; VIRUS LOAD;

ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INFANT; INTERFERON-ALPHA; INTERLEUKINS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; SUSTAINED VIROLOGIC RESPONSE; VIRAL LOAD;

EID: 84994716173     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.16220     Document Type: Article

References (28)

1. Wirth S, Lang T, Gehring S, et al. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology. 2002; 36: 1280-4.
2. Kjaergard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ. 2001; 323: 1151-5.
3. Mangi A, Villani MR, Minerva N, et al. Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: a randomized controlled trial. J Hepatol. 2001; 34: 441-6.
4. Druyts E, Mills EJ, Nachega J, et al. Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis. Clin Exp Gastroenterol. 2012; 5: 11-21.
5. Awad T, Thorlund K, Hauser G, et al. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology. 2010; 51: 1176-84.
6. Christensson B, Wiebe T, Akesson A, et al. Interferon-alpha and ribavirin treatment of hepatitis C in children with malignancy in remission. Clin Infect Dis. 2000; 30: 585-6.
7. Lackner H, Moser A, Deutsch J, et al. Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy. Pediatrics. 2000; 106: E53.
8. El-Shabrawi MH, Kamal NM. Burden of pediatric hepatitis C. World J Gastroenterol. 2013; 19: 7880-8.
9. Süoğlu, Elkabes B, Sökücü S, et al. Does interferon and ribavirin combination therapy increase the rate of treatment response in children with hepatitis C. J Pediatr Gastroenterol Nutr. 2002; 34: 199-206.
10. Süoğlu, Elkabes B, Sökücü S, et al. Does interferon and ribavirin combination therapy increase the rate of treatment response in children with hepatitis C. J Pediatr Gastroenterol Nutr. 2002; 34: 199-206.
11. Pineda JA, Caruz A, Rivero A, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 2010; 51: 788-95.
12. McCarthy JJ, Li JH, Thompson A, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology. 2010; 138: 2307-14.
13. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014; 60: 392-420.
14. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461: 399-401.
15. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461: 798-801.
16. Urban TJ, Thompson AJ, Bradrick SS, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology. 2010; 52: 1888-96.
17. Tillmann HL, Thompson AJ, Patel K, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology. 2010; 139: 1586-92, 1592.e1.
18. Montes-Cano MA, García-Lozano JR, Abad-Molina C, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology. 2010; 52: 33-7.
19. Lin CY, Chen JY, Lin TN, et al. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One. 2011; 6: e18322.
20. González-Peralta RP, Kelly DA, Haber B, et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology. 2005; 42: 1010-8.
21. Figlerowicz M, Sluzewski W, Kowala-Piaskowska A, et al. Interferon alpha and ribavirin in the treatment of children with chronic hepatitis C. Eur J Pediatr. 2004; 163: 265-7.
22. Druyts E, Thorlund K, Wu P, et al. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Clin Infect Dis. 2013; 56: 961-7.
23. González-Peralta RP, Kelly DA, Haber B, et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology. 2005; 42: 1010-8.
24. Chen JY, Lin CY, Wang CM, et al. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection. Genes Immun. 2011; 12: 300-9.
25. Kim KH, Jang BK, Chung WJ, et al. Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis. Korean J Hepatol. 2011; 17: 220-5.
26. Rivero-Juárez A, Camacho EA, Perez-Camacho I, et al. Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4. J Antimicrob Chemother. 2012; 67: 202-5.
27. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010; 139: 120-9.e18.
28. Chevaliez S, Hézode C, Soulier A, et al. High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial). Gastroenterology. 2011; 141: 119-27.